Annovis Bio expects cash to fund operations through March 2027 Alzheimer's trial readout
ANVS•Annovis Bio expects proceeds from a $21 million public offering and existing cash to fund operations through its pivotal Phase 3 Alzheimer's data readout in March 2027.
1. Funding and trial plans
Annovis Bio expects proceeds from its $21 million public offering and existing cash to fund operations through its pivotal Phase 3 Alzheimer's data readout in March 2027. The proceeds will also support continued clinical development of buntanetap for Alzheimer's and Parkinson's diseases.
